Table 3 Cox regression factors affecting OS/DFS/relapse in patients with MC.

From: Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study

N = 106 patients

OS(UV/MV)

  

DFS(UV/MV)

  

Relapse (UV/MV)

  
 

HR (UV/MV)

CI (UV/MV)

P (UV/MV)

HR (UV/MV)

CI UV/MV)

P (UV/MV)

HR (UV/MV)

CI (UV/MV)

P (UV/MV)

Conditioning regimen (ref RIC)

0.93

0.7–1.2

0.66

1.01

0.7–1.2

0.88

0.95

0.6–1.3

0.78

Disease risk (DRI, ref high risk)

1.1

0.5–2.3

0.65

1.17

0.6–2.2

0.61

1.12

0.5–2.4

0.76

Age (ref > 52)

1.34

0.7–2.3

0.34

1.12

0.5–1.9

0.58

1.11

0.6–2.1

0.73

Presence of cGVHD (ref yes)

1.08

0.5–2.0

0.79

0.83

0.4–1.4

0.53

0.76

0.3–1.5

0.45

Matching (ref 9/10)

0.64

0.3–1.2

0.17

0.75

0.4–1.3

0.31

0.73

0.3–1.5

0.39

CD 3 day 60 (ref < 50)

1.24

0.6–2.2

0.55

1.23

0.6–2.1

0.49

0.90

0.4–1.8

0.78

Response to pDLI (No response vs response)

5.95/5.9

2.3–15/2.3–15

0.001/ 0.001

5.45/5.4

2.4–12/2.4–12

0.0001/ 0.0001

9.45/9.4

2.8–30/2.8–30

0.0001/ 0.0001

Presence of severe cGVHD (ref yes)

1.42

0.6–3.5

0.37

1.09

0.4–2.5

0.82

0.78

0.2–2.5

0.68

  1. OS overall survival, DFS disease-free survival, GVHD graft vs host disease, BM bone marrow, NRM non-relapse mortality, MA myeloablative regimen, RIC reduced-intensity conditioning, MC mixed chimerism, pDLI pre-emptive donor lymphocyte infusion.
Back to article page